CurrentBlue Cross Blue Shield - IowaPolicy 05.01.08

Monoclonal antibodies for prevention of RSV (palivizumab, nirsevimab, clesrovimab)

Defines medical necessity criteria, quantity limits, dosing, and billing codes for Synagis (palivizumab) and states coverage policies for Beyfortus (nirsevimab) and Enflonsia (clesrovimab) for prevention of RSV in infants and young children, including authorization rules, season dates, and restrictions on concomitant use.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyMonoclonal antibodies for prevention of RSV (palivizumab, nirsevimab, clesrovimab)

Policy CodePolicy 05.01.08

Change TypeRevised (Aug 2025)

Effective DateOct 11, 2025

Next Review Date

Key ActionAuthorization is required for Synagis requests per criteria and dosing limits; Beyfortus (≤24 months) and Enflonsia (≤12 months) meeting ACIP recommendations are covered without prior authorization.

SourceLink

POLICY UPDATE CHANGES

Policy reviewed and revised August 2025; Effective October 11, 2025.

5Maximum doses per RSV season for Synagis

24 moBeyfortus no-PA age limit

12 moEnflonsia no-PA age limit

>=3%RT-PCR RSV activity threshold for off-season Synagis dosing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

2025-11-01 to 2026-04-30Wellmark RSV season 2025-2026

Coverage Summary

Policy governs prophylactic use of monoclonal antibodies to prevent RSV lower respiratory tract disease in high-risk infants and children and addresses Synagis (palivizumab), Beyfortus (nirsevimab), and Enflonsia (clesrovimab). The policy aligns coverage with FDA labeling and ACIP/AAP guidance and specifies the Wellmark RSV season dates for 2025-2026 as November 1, 2025 to April 30, 2026. Overall coverage stance is mixed: Synagis is subject to medical necessity criteria and prior authorization, while Beyfortus and Enflonsia have specific coverage without prior authorization per ACIP/AAP recommendations.

Key thresholds and season dates

Synagis dosing limitMaximum 5 doses per RSV season

RSV activity threshold for off-season>= 3% (RT-PCR) within 2 weeks of intended dose per CDC NREVSS

Oxygen requirement for CLD>21% oxygen for at least 28 days after birth

Wellmark RSV season 2025-2026November 1, 2025 - April 30, 2026

Initial Approval - Synagis (palivizumab)

Synagis may be considered medically necessary when ALL of the following applicable criteria for each indication are met:

Indications

Very preterm infants
- Infant born at less than 29 weeks' gestation (28 weeks, 6 days and earlier)
- Younger than 12 months of age at the onset of RSV season
Chronic lung disease of prematurity (CLD/ BPD)
- Born before 32 weeks gestation (31 weeks, 6 days and earlier)
- Chronic lung disease defined as >21% oxygen requirement for at least 28 days after birth

Not Medically Necessary / Exclusions

Not Medically Necessary

Synagis is considered not medically necessary when the patient does not meet the above criteria.

Patient does not meet any of the specified indication criteria for Synagis

Product-specific Coverage without Prior Authorization

Product-Specific Coverage without Prior Authorization

Beyfortus and Enflonsia coverage statements

Beyfortus (nirsevimab) is covered without prior authorization for members 24 months and younger, including additional doses required for members undergoing cardiac surgery with cardiopulmonary bypass during their first or second RSV season

Enflonsia (clesrovimab) is covered without prior authorization for members 12 months and younger

Patients meeting ACIP recommendations do not require review and are covered without prior authorization

Beyfortus (nirsevimab) is covered without prior authorization for members 24 months and younger, and Enflonsia (clesrovimab) is covered without prior authorization for members 12 months and younger. Patients who meet ACIP recommendations do not require review and are covered without prior authorization.

Concomitant Use and Off-Season Dosing

Restrictions and criteria for off-season use:

Patient cannot receive Synagis concomitantly with either Beyfortus or Enflonsia during the same RSV season

>= 3% (RT-PCR) RSV activity within 2 weeks of the intended dose per CDC NREVSS

For off-season Synagis requests, authorization of 1 dose per request (up to maximum of 5 doses per RSV season) may be granted if threshold met; local health department or CDC NREVSS will be consulted

Initial criteria and quantity/dosing limits apply to off-season authorizationsMaximum 5 doses per RSV season

Off-season threshold and consultation

Provider Actions (Prior Authorization, Documentation, Billing)

Prior Authorization

Authorization required for Synagis

Authorization is required for Synagis (palivizumab) prior to administration. Requests for Synagis will be reviewed against medical necessity criteria in this policy; approvals will be issued when criteria are met.

Affected codes: HCPCS 90378, S9562
Exemptions: Beyfortus (nirsevimab) and Enflonsia (clesrovimab) are covered without prior authorization per policy and do not require a Synagis PA
Off-season Synagis: PA still required; off-season single-dose requests evaluated per regional RSV activity criteria

Documentation Required

Document indication and age/gestational criteria

Document the indication and clinical details supporting medical necessity when submitting a prior authorization for Synagis. Include clear evidence for age, gestational history, and condition-specific criteria.

Gestational age at birth (weeks + days)

Applicable Codes

Covered HCPCS / Provider drug codesHCPCSCovered

90380	Beyfortus (respiratory syncytial virus, monoclonal antibody) Injection, 0.5 mL
90378	Respiratory syncytial virus, monoclonal antibody, recombinant; for intramuscular use, 50 mg, each
90381	Beyfortus (respiratory syncytial virus, monoclonal antibody) Injection, mL
90382	Enflonsia (respiratory syncytial virus, monoclonal antibody) Injection, 0.7 mL
S9562	Home injectable therapy, palivizumab, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Clinical Evidence

~50%Reduction in RSV hospitalizations with palivizumab (trial headline)

16NNT — premature infants

20NNT — chronic lung disease (CLD)

23NNT — hemodynamically significant CHD

Evidence from randomized controlled trials of palivizumab demonstrated approximately a 50% reduction in RSV-related hospitalizations, with numbers needed to treat of 16 (premature infants), 20 (chronic lung disease), and 23 (congenital heart disease). ACIP has provided recommendations for Beyfortus and Enflonsia consistent with product approvals and public health guidance.

Background

This policy defines the medical necessity criteria and operational rules for prophylactic monoclonal antibodies to prevent RSV lower respiratory tract disease in high-risk infants and children, including Synagis (palivizumab) and the newer single-dose products Beyfortus (nirsevimab) and Enflonsia (clesrovimab). Coverage and use are aligned with FDA labeling, ACIP and AAP recommendations, and clinical evidence. Wellmark frames the RSV season for 2025-2026 as November 1, 2025 to April 30, 2026, and includes product-specific guidance on prior authorization, dosing limits, and restrictions on concomitant use.

Chronic lung disease of prematurity (CLD) is defined as a requirement for >21% supplemental oxygen for at least 28 days after birth. Wellmark's RSV season dates for 2025-2026 are November 1, 2025 to April 30, 2026.

Revision History

2025-08-01reviewed

Policy reviewed and revised to incorporate updated ACIP/AAP recommendations and add coverage language for Beyfortus and Enflonsia without prior authorization and to set season dates for 2025-2026.

2025-10-11effective_dateLatest

Revised policy became effective, incorporating the August 2025 changes including coverage without prior authorization for Beyfortus (up to 24 months) and Enflonsia (up to 12 months), off-season Synagis thresholds, and Wellmark RSV season dates for 2025-2026.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyMonoclonal antibodies for prevention of RSV (palivizumab, nirsevimab, clesrovimab)

Policy CodePolicy 05.01.08

Change TypeRevised (Aug 2025)

Effective DateOct 11, 2025

Next Review Date

SourceLink

On This Page

>21% oxygen for at least 28 days after birth

Age criteria (ONE of)

Younger than 12 months of age at the onset of RSV season
Younger than 24 months of age at the start of RSV season AND has continued to require medical therapy (e.g., supplemental oxygen, diuretic therapy, chronic corticosteroid therapy) during the 6-month period prior to the start of the RSV season

Hemodynamically significant congenital heart disease (CHD)

Patient is less than 12 months of age at the onset of RSV season
CHD subcriteria (ONE of)
- Moderate to severe pulmonary hypertension
- Acyanotic heart disease for which the patient is receiving medication to control congestive heart failure AND will require cardiac surgical procedures
- Cyanotic heart disease in consultation with a pediatric cardiologist

Post-cardiac transplantation

Infants and children younger than 24 months of age at the onset of RSV season
Have undergone cardiac transplantation during RSV season

Congenital airway or neuromuscular disorders

Infant with congenital abnormalities of the airways or neuromuscular condition that compromises the handling of secretions
Patient is younger than 12 months of age at the onset of RSV season

Profoundly immunocompromised

Infants and children younger than 24 months of age at the onset of RSV season
Profoundly immunocompromised (e.g., solid organ transplant, hematopoietic stem cell transplant, receiving chemotherapy)

Cystic fibrosis with severe manifestations

Age and severity criteria (ONE of)
- Younger than 12 months: Patient is less than 12 months of age at the onset of RSV season
  Has ONE of: nutritional compromise OR manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormal chest radiography/CT that persists when stable)
- Up to 24 months: Patient is less than 24 months of age at the onset of RSV season
  Has ONE of: weight for length less than 10th percentile OR manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormal chest radiography/CT that persists when stable)

General dosing limit when approved

Approval will be for a maximum of 5 doses per RSV seasonMaximum 5 doses per RSV season
Additional postoperative dose may be considered following cardiopulmonary bypass or conclusion of extracorporeal membrane oxygenation for children with heart disease meeting criteria

Off-season RSV activity threshold>= 3% RT-PCR within 2 weeks of the intended dose (per CDC NREVSS)

Operational consultation ruleLocal health department or CDC NREVSS will be consulted to assess regional/state RSV activity for off-season dosing

Off-season dosing quantityAuthorization of 1 dose per request; initial criteria and quantity/dosing limits apply; up to maximum of 5 doses per RSV season

Chronological age at onset of RSV season / at time of request

For CLD/bronchopulmonary dysplasia: evidence of >21% oxygen requirement for ≥28 days after birth and documentation of ongoing therapies (supplemental oxygen, diuretics, chronic corticosteroids) in the 6 months prior to RSV season when applicable

For CHD: details of diagnosis, evidence of hemodynamically significant CHD (e.g., pulmonary hypertension, medications for heart failure), and pediatric cardiology consultation notes if applicable

Transplant or immunocompromised status: date/type of transplant or chemotherapy/HSCT details and current immunosuppressive regimen

Cystic fibrosis: documentation of nutritional compromise or manifestations of severe lung disease (prior hospitalizations for pulmonary exacerbation, abnormal chest imaging)

Timing of cardiac surgery with cardiopulmonary bypass if requesting additional postoperative dose

Billing Rule

Dosing and quantity limits

Dosing and quantity limits must be followed for Synagis. Submit requests that reflect the recommended dose and seasonal quantity limits; doses given outside the defined season or prior to the season start have specific counting rules.

Dosing: Synagis (palivizumab) 15 mg/kg intramuscular once monthly
Quantity limit: maximum 5 doses per RSV season
Season counting rule: doses received prior to November 1 do NOT count toward the 2025-2026 season 5-dose total
Affected codes: HCPCS 90378, S9562

Denial Risk

Denial if criteria not met

Requests for Synagis that do not meet the policy criteria or lack required documentation may be denied. Ensure all clinical criteria and supporting documentation are included with the PA submission to avoid denial.

Denial risk for requests lacking age/gestational evidence, missing disease-specific documentation, or requesting Synagis concomitantly with Beyfortus/Enflonsia in the same RSV season
Denial risk for requests exceeding dosing/quantity limits or not aligned with regional RSV activity rules for off-season doses

Step Therapy

Product preference and no PA for ACIP-eligible Beyfortus/Enflonsia

Product preference guidance: ACIP/AAP–recommended products (Beyfortus/Enflonsia) are preferred for eligible infants and do not require prior authorization per this policy. Synagis should not be used in the same RSV season as Beyfortus or Enflonsia.

Preferred products without PA when ACIP-eligible: Beyfortus (nirsevimab) HCPCS 90380; Enflonsia (clesrovimab) HCPCS 90381, 90382 (as applicable)
Guidance: Beyfortus is preferred per AAP/ACIP recommendations for eligible infants; do not administer Synagis in the same RSV season if Beyfortus or Enflonsia has been given